« Back
Home /
CDDO-EA

CDDO-EA

Item no.	HY-12213-1mg
Manufacturer	MedChem Express
CASRN	932730-51-3
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.78
Citations	[1]Neymotin A, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011 Jul 1;51(1):88-96.\|[2]Liby K, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007 Mar 15;67(6):2414-9.
Smiles	O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]3(C)[C@@]4([H])[C@@]5([H])[C@@](CCC(C)(C)C5)(C(NCC)=O)CC3)(C)C2=CC4=O)([H])C1(C)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CDDO ethyl amide,TP319,RTA 405
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Keap1-Nrf2
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	518.73
Product Description	CDDO-EA is an NF-E2 related factor 2/antioxidant response element (Nrf2/ARE) activator.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturer - Pathway	NF-κB
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.